The European Commission announced a comprehensive plan to combat multidrug-resistant bacteria. Officials will take advantage of the private-public Innovative Medicines Initiative to promote "unprecedented open sharing of knowledge" among drugmakers during the pre-competitive stage of research and development. The commission also promised more flexible legislation for faster approval of novel antibiotics and to collaborate with governments for "adequate market and pricing conditions."

Full Story:

Related Summaries